Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 8/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.51 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | BCR | P11274 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044897 | 0.80 | DDR1 (0.41) | DDR1KITABL1BCRKDR | |
| SCHEMBL111003 | 0.76 | KDR (0.60) | DDR1KITABL1BCRKDR | |
| SCHEMBL22044025 | 0.76 | DDR1 (0.74) | DDR1KITABL1BCRKDR | |
| SCHEMBL22044064 | 0.74 | NPSR1 (0.40) | DDR1KITABL1BCRKDR | |
| SCHEMBL2663392 | 0.72 | CHEK1 (0.50) | DDR1KITABL1BCRKDR | |
| SCHEMBL22044103 | 0.69 | DDR1 (0.66) | DDR1KITABL1BCRDDR2 | |
| SCHEMBL24576573 | 0.69 | DYRK1A (0.58) | GSK3B | |
| SCHEMBL29775130 | 0.69 | DYRK1A (0.58) | GSK3B | |
| SCHEMBL29775068 | 0.69 | EGFR (0.56) | — | |
| SCHEMBL24577018 | 0.69 | EGFR (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | DDR1 3947/4885KIT 287/4885ABL1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.